Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 381-387

  Nyboe, L ^a   Vestergaard, C H ^a   Moeller, M K ^b   Lund, H ^c,d   Videbech, P ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HORSENS REGIONAL HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d BERGEN UNIVERSITY COLLEGE   (Norway)

Author keywords

Aerobic fitness; First episode schizophrenia; Lifestyle habits; Metabolic syndrome; Physical activity

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRIACYLGLYCEROL;

ADULT; AEROBIC EXERCISE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIET RESTRICTION; EATING HABIT; FEMALE; FITNESS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SLEEP DISORDER; WAIST CIRCUMFERENCE; ADOLESCENT; COMPLICATION; KINESIOTHERAPY; METABOLIC DISEASES; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; EXERCISE THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; MOTOR ACTIVITY; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84942365043     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.07.053     Document Type: Article

References (50)

1. Aadahl M., Jorgensen T. Validation of a new self-report instrument for measuring physical activity. Med. Sci. Sports Exerc. 2003, 35(7):1196-1202.
2. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 2006, 23(5):469-480.
3. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 2001, 62(Suppl. 7):22-31.
4. Andersen L.G., Groenvold M., Jorgensen T., Aadahl M. Construct validity of a revised Physical Activity Scale and testing by cognitive interviewing. Scand. J. Public Health 2010, 38(7):707-714.
5. Andreasen N.C. Scale for Assessment of Positive Symptoms 1984, University of Iowa, Iowa City.
6. Andreasen N.C. Scale for Assessment of Negative Symptoms. Springer Healthcare 1984, University of Iowa, Iowa City. 3rd ed.
7. Astrand I. Aerobic work capacity in men and women with special reference to age. Acta Physiol. Scand. Suppl. 1960, 49(169):1-92.
8. Beary M., Hodgson R., Wildgust H.J. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J. Psychopharmacol. 2012, 26(5 Suppl.):52-61.
9. Bensenor I.M., Brunoni A.R., Pilan L.A., Goulart A.C., Busatto G.F., Lotufo P.A., Scazufca M., Menezes P.R. Cardiovascular risk factors in patients with first-episode psychosis in Sao Paulo, Brazil. Gen. Hosp. Psychiatry 2012, 34(3):268-275.
10. Boden R., Haenni A., Lindstrom L., Sundstrom J. Biochemical risk factors for development of obesity in first-episode schizophrenia. Schizophr. Res. 2009, 115(2-3):141-145.
11. Boke O., Aker S., Sarisoy G., Saricicek E.B., Sahin A.R. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int. J. Psychiatry Med. 2008, 38(1):103-112.
12. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br. J. Psychiatry 2010, 196(2):116-121.
13. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28(2):193-213.
14. Chiliza B., Asmal L., Oosthuizen P., Van Niekerk E., Erasmus R., Kidd M., Malhotra A., Emsley R. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic. Eur. Psychiatry 2015, 30(2):277-283.
15. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry 2004, 49(11):753-760.
16. Correll C.U., Robinson D.G., Schooler N.R., Brunette M.F., Mueser K.T., Rosenheck R.A., Marcy P., Addington J., Estroff S.E., Robinson J., Penn D.L., Azrin S., Goldstein A., Severe J., Heinssen R., Kane J.M. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 2014, 71(12):1350-1363.
17. De Hert M., Peuskens J., van Winkel R. Mortality in patients with schizophrenia. Lancet 2009, 374(1474-547; 9701):1591-1593.
18. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011, 8(2):114-126.
19. Eriksen L., Grønbæk M., Helge J.W., Tolstrup J.S., Curtis T. The Danish Health Examination Survey 2007-2008 (DANHES 2007-2008). Scand. J. Public Health 2011, 39(2):203-211.
20. Fleischhacker W.W., Siu C.O., Boden R., Pappadopulos E., Karayal O.N., Kahn R.S., EUFEST study group Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int. J. Neuropsychopharmacol. 2013, 16(5):987-995.
21. Graham K.A., Cho H., Brownley K.A., Harp J.B. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr. Res. 2008, 101(1-3):287-294.
22. Huang Y., Liu X. Leisure-time physical activity and the risk of metabolic syndrome: meta-analysis. Eur. J. Med. Res. 2014, 19:1-8.
23. Jennings J.R., Muldoon M.F., Hall M., Buysse D.J., Manuck S.B. Self-reported sleep quality is associated with the metabolic syndrome. Sleep 2007, 30(2):219-223.
24. Jin H., Folsom D., Sasaki A., Mudaliar S., Henry R., Torres M., Golshan S., Glorioso D.K., Jeste D. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr. Res. 2011, 125(2-3):295-299.
25. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., Tang W., Wiener K., Dvorin S., Dietz M.B. Prevalence of the metabolic syndrome among patients receiving clozapine. Am. J. Psychiatry 2006, 163:1273-1276.
26. Laursen T.M. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr. Res. 2011, 131(1-3):101-104.
27. Laursen T.M., Nordentoft M., Mortensen P.B. Excess early mortality in schizophrenia. Annu. Rev. Clin. Psychol. 2014, 10:425-448.
28. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382(9896):951-962.
29. Leyk D., Ruther T., Witzki A., Sievert A., Moedl A., Blettner M., Hackfort D., Lollgen H. Physical fitness, weight, smoking, and exercise patterns in young adults. Dtsch. Arztebl. Int. 2012, 109(44):737-745.
30. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott S.T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80(1):19-32.
31. Minder C.M., Shaya G.E., Michos E.D., Keenan T.E., Blumenthal R.S., Nasir K., Carvalho J.A., Conceicao R.D., Santos R.D., Blaha M.J. Relation between self-reported physical activity level, fitness, and cardiometabolic risk. Am. J. Cardiol. 2014, 113(4):637-643.
32. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr. Bull. 2011, 39(2):306-318.
33. Mitchell A.J., Vancampfort D., De Herdt A., Yu W., De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr. Bull. 2013, 39(2):295-305.
34. Mottillo S., Filion K.B., Genest J., Joseph L., Pilote L., Poirier P., Rinfret S., Schiffrin E.L., Eisenberg M.J. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010, 56(14):1113-1132.
35. Nielsen J., Skadhede S., Correll C.U. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010, 35(9):1997-2004.
36. Nyboe L., Vestergaard C., Moller M., Lund H., Videbech P. Metabolic Syndrome in First-time Hospitalised Patients with Depression. A one year follow-up study 2015, (submitted for publication).
37. Perez-Iglesias R., Martinez-Garcia O., Pardo-Garcia G., Garcia-Unzueta M.T., Tabares-Seisdedos R., Crespo-Facorro B. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int. J. Neuropsychopharmacol. 2014, 17(1):41-51.
38. Phutane V.H., Tek C., Chwastiak L., Ratliff J.C., Ozyuksel B., Woods S.W., Srihari V.H. Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention?. Schizophr. Res. 2011, 127(1-3):257-261.
39. Povel C.M., Boer J.M., Reiling E., Feskens E.J. Genetic variants and the metabolic syndrome: a systematic review. Obes. Rev. 2011, 12(11):952-967.
40. Saari K.M., Lindeman S.M., Viilo K.M., Isohanni M.K., Jarvelin M.R., Lauren L.H., Savolainen M.J., Koponen H.J. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J. Clin. Psychiatry 2005, 66(5):559-563.
41. Saddichha S., Ameen S., Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J. Clin. Psychopharmacol. 2008, 28(1):27-31.
42. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr. Res. 2008, 101(1-3):266-272.
43. Srisawat U., Reynolds G.P., Zhang Z.J., Zhang X.R., Arranz B., San L., Dalton C.F. Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. Int. J. Neuropsychopharmacol. 2014, 17(3):485-490.
44. Sun K., Liu J., Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. PLoS One 2012, 7(10):e47791.
45. Tarricone I., Ferrari Gozzi B., Gireco D., Berardi D. Weight gain in anti-psychotic-naïve patients: a review and meta-analysis. Psychol. Med. 2010, 40(2):187-200.
46. Taylor D., Paton C., Kapur S. The Maudsley Prescribing Guidelines 2012, Wiley-Blackwell, UK. 11th ed.
47. Vancampfort D., Wampers M., Mitchell A.J., Correll C.U., De Herdt A., Probst M., De Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013, 12(3):240-250.
48. Vancampfort D., Guelinckx H., De Hert M., Stubbs B., Soundy A., Rosenbaum S., De Schepper E., Probst M. Reliability and clinical correlates of the Astrand-Rhyming sub-maximal exercise test in patients with schizophrenia or schizoaffective disorder. Psychiatry Res. 2014, 220(3):778-783.
49. Vishram J.K., Borglykke A., Andreasen A.H., Jeppesen J., Ibsen H., Jorgensen T., Palmieri L., Giampaoli S., Donfrancesco C., Kee F., Mancia G., Cesana G., Kuulasmaa K., Salomaa V., Sans S., Ferrieres J., Dallongeville J., Soderberg S., Arveiler D., Wagner A., Tunstall-Pedoe H., Drygas W., Olsen M.H., Project M.O.R.G.A.M. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS One 2014, 9(9):1-12.
50. Wu X., Huang Z., Han H., Zhong Z., Gan Z., Guo X., Diao F., Han Z., Zhao J. The comparison of glucose and lipid metabolism parameters in drug-naive, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia. Neuropsychiatr. Dis. Treat. 2014, 10:1361-1368.